Movers & Shakers Archives - Page 30 of 31

1 minute read

Why Roblox Shares Are Lower On Friday

July 22, 3:07 PM

Today has been a rough day for social media stocks following a poor earnings report from Snap, Inc. (NYSE: SNAP). Snap’s report is having an impact on social media and gaming companies such as Roblox Corp.

RBLX

2 minute read

Strategic Cannabis Execs Making Changes At Companies You Know: Curaleaf, Valens, Copperstate & Delic

By Jelena Martinovic

July 22, 12:49 PM

As Benzinga Cannabis Capital Conference returns (September 13-14) in Chicago, gathering top CEOs, investors and leaders in the cannabis industry, let's scroll through the latest leadership changes within the space.

CSE:DELC

1 minute read

Why Shares Of Boston Beer Are Falling Today

By Dylan Wechsler

July 22, 9:33 AM

Shares of Boston Beer Company Inc (NYSE: SAM) are trading lower Friday after the company reported worse-than-expected Q2 sales results and cut its FY22 EPS guidance. The company reported earnings per share of $4.31 versus the $5.35 analysts were expecting.

SAM

1 minute read

Why Shares of Exxon Mobil Are Trading Lower Today

By Dylan Wechsler

July 21, 9:18 AM

Exxon Mobil Corp. (NYSE: XOM) shares are trading lower this morning amid a drop in oil prices. Oil has pulled back following a recent rise in US gasoline inventories.

XOM

2 minute read

Why Did Warren Buffett Get Confused By FINRA And Fractional Trading: New Rule Causes Surge In BRK.A’s Reported Trading Volume

By Dylan Wechsler

July 20, 6:44 PM

Berkshire Hathaway, Inc.

BRK-A

1 minute read

Rhythm Shares Shoot Higher Following Pre-marketing Authorization From French Regulatory For Multisystem Disorder Candidate

By Ragothaman Srinivasan

July 20, 10:30 AM

The French National Agency for Medicines and Health Products Safety (ANSM) and Haute Autorité de santé (HAS) have granted pre-marketing authorization AP1 (early access authorization), for Rhythm Pharmaceuticals’ (NASDAQ: RYTM) lead candidate IMCIVREE (setmelanotide) in patients with genetically-conf

RYTM

1 minute read

Sorrento Shares Gain Following FDA’s Nod for Initial-Stage Covid-19 Study

By Ragothaman Srinivasan

July 19, 3:20 PM

Sorrento Therapeutics (NASDAQ: SRNE) announced that the U.S. Food and Drug Administration (FDA) has cleared the Phase 1 study of its candidate, STI-1558, in patients with impaired renal and hepatic function.

SRNE

1 minute read

Apellis Shares Climb As FDA Accepts Geographic Atrophy Candidate Submission Under Priority Review

By Ragothaman Srinivasan

July 19, 8:22 AM

The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation for Apellis Pharmaceuticals’ (NASDAQ: APLS) New Drug Application (NDA) for the intravitreal pegcetacoplan. The regulatory agency has assigned target action date of November 26, 2022.

APLS

1 minute read

Avadel Secures FDA Tentative Approval For Excessive Daytime Sleepiness (EDS) Candidate

By Ragothaman Srinivasan

July 19, 7:59 AM

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.

AVDL

1 minute read

NexImmune Shares Soar Following FDA’s Clearance To Initial-Stage HPV Cancer Study

By Ragothaman Srinivasan

July 14, 5:24 PM

NexImmune, Inc. (NASDAQ: NEXI) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for its first cellular therapy product candidate NEXI-003 addressing solid tumors.

NEXI